---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-102027"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:29:48.336659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics Q2 net loss $208.5M; CASGEVY hits 75 ATCs, 115 cell collections; CTX310 shows 86% LDL reduction

## Summary
- Net loss of $208.5M in Q2 2025 vs $126.4M in Q2 2024; cash & securities $1.72B down from $1.90B at end-2024.
- CASGEVY momentum: >75 authorized treatment centers activated, ~115 patients had cells collected, 29 received infusions (16 in Q2).
- CTX310 Phase 1 data: dose-dependent TG reduction up to 82% and LDL reduction up to 86% after single administration; full data H2 2025.
- EMA authorized Phase 2 trial for SRSD107 (Factor XI siRNA) in thromboembolic disorders; $25M upfront to partner Sirius Therapeutics.

## SEC filing metadata
- accession: 0000950170-25-102027
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017025102027/0000950170-25-102027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017025102027/crsp-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-102027
- JSON: https://secwatch.observer/filing/0000950170-25-102027.json
- Plain text: https://secwatch.observer/filing/0000950170-25-102027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.